Literature DB >> 17097248

Functional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studies.

Sheetal Agarwal1, Ritesh Jain, Dhananjay Pal, Ashim K Mitra.   

Abstract

MDCKII-MDR1 cell line has been extensively selected as a model to study P-gp-mediated drug efflux. Recently, investigators have employed this cell line for studying influx of peptide prodrug derivatives of parent compounds, which are P-gp substrates. Therefore, the objective of this study is to functionally characterize the peptide mediated uptake and transport of [(3)H] Glycylsarcosine ([(3)H] Gly-Sar), a model peptide substrate across MDCKII-MDR1 cells. [(3)H] Gly-Sar uptake from apical (AP) and basolateral (BL) membranes was found to be time-dependent and saturable. Michaelis-Menten (K(m)) constants of [(3)H] Gly-Sar uptake across the AP and BL directions in MDCKII-MDR1 cell line were found to be 457+/-37 and 464+/-85microM, respectively. V(max) values in AP and BL directions for the peptide transporters in MDCKII-MDR1 cell line were calculated to be 0.035+/-0.001 and 0.35+/-0.034pmol/minmg protein, respectively. Uptake of [(3)H] Gly-Sar was significantly inhibited in the presence of aminocephalosporins and ACE-Inhibitors, known substrates for peptide transporters in both the AP and BL directions. Permeability of [(3)H] Gly-Sar in the BL direction was maximal at pH 4 as compared to pH 5, 6 and 7.4 whereas such permeability in the AP direction was optimal at pH 7.4. Transepithelial transport of [(3)H] Gly-Sar in the AP-BL direction was significantly lower than from BL-AP direction at all observed pHs. No statistical difference was observed in the transepithelial permeability of [(3)H] Gly-Sar across both AP and BL directions over 4-10 days of growth period. The present study indicates that peptide transporters are effectively involved in the bidirectional transport of Gly-Sar across MDCKII-MDR1 cell line; the BL peptide transporter can transport Gly-Sar at a greater rate as compared to the AP peptide transporter. Results from these studies suggest the application of MDCKII-MDR1 cell line as a rapid effective tool to study peptide mediated influx of compounds that may be substrates for both P-gp and peptide transporters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097248      PMCID: PMC1987333          DOI: 10.1016/j.ijpharm.2006.09.056

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  20 in total

1.  Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.

Authors:  K Ito; H Kusuhara; Y Sugiyama
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

2.  Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.

Authors:  Ritesh Jain; Sheetal Agarwal; Soumyajit Majumdar; Xiaodong Zhu; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2005-10-13       Impact factor: 5.875

3.  Plant polyphenols and multidrug resistance: effects of dietary flavonoids on drug transporters in Caco-2 and MDCKII-MDR1 cell transport models.

Authors:  R Rodriguez-Proteau; J E Mata; C L Miranda; Y Fan; J J Brown; D R Buhler
Journal:  Xenobiotica       Date:  2006-01       Impact factor: 1.908

Review 4.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

5.  Functional expression of novel peptide transporter in renal basolateral membranes.

Authors:  T Terada; K Sawada; T Ito; H Saito; Y Hashimoto; K Inui
Journal:  Am J Physiol Renal Physiol       Date:  2000-11

6.  Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.

Authors:  Marielle Rouquayrol; Bérangère Gaucher; Dominique Roche; Jacques Greiner; Pierre Vierling
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

7.  New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.

Authors:  C Rousselle; P Clair; J M Lefauconnier; M Kaczorek; J M Scherrmann; J Temsamani
Journal:  Mol Pharmacol       Date:  2000-04       Impact factor: 4.436

8.  Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization.

Authors:  Ritesh Jain; Soumyajit Majumdar; Yasser Nashed; Dhananjay Pal; Ashim K Mitra
Journal:  Mol Pharm       Date:  2004 Jul-Aug       Impact factor: 4.939

9.  Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.

Authors:  K S Lown; R R Mayo; A B Leichtman; H L Hsiao; D K Turgeon; P Schmiedlin-Ren; M B Brown; W Guo; S J Rossi; L Z Benet; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

Review 10.  P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.

Authors:  Manthena V S Varma; Yasvanth Ashokraj; Chinmoy S Dey; Ramesh Panchagnula
Journal:  Pharmacol Res       Date:  2003-10       Impact factor: 7.658

View more
  8 in total

1.  Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.

Authors:  Mitesh Patel; Ye Sheng; Nanda K Mandava; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2014-09-26       Impact factor: 5.875

2.  Prodrug approach to improve absorption of prednisolone.

Authors:  Ye Sheng; Xiaoyan Yang; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2015-04-15       Impact factor: 5.875

3.  Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis.

Authors:  Mitan R Gokulgandhi; Megha Barot; Mahuya Bagui; Dhananjay Pal; Ashim K Mitra
Journal:  J Pharm Sci       Date:  2012-04-12       Impact factor: 3.534

4.  Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.

Authors:  Sheetal Agarwal; S H S Boddu; Ritesh Jain; Swapan Samanta; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-03-28       Impact factor: 5.875

Review 5.  Advances in the use of prodrugs for drug delivery to the eye.

Authors:  Pranjal Taskar; Akshaya Tatke; Soumyajit Majumdar
Journal:  Expert Opin Drug Deliv       Date:  2016-07-21       Impact factor: 6.648

6.  Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines.

Authors:  Zhiying Wang; Dhananjay Pal; Ashaben Patel; Deep Kwatra; Ashim K Mitra
Journal:  Int J Pharm       Date:  2012-12-20       Impact factor: 5.875

7.  Mitochondrial localization of P-glycoprotein and peptide transporters in corneal epithelial cells--novel strategies for intracellular drug targeting.

Authors:  Megha Barot; Mitan R Gokulgandhi; Dhananjay Pal; Ashim K Mitra
Journal:  Exp Eye Res       Date:  2012-10-29       Impact factor: 3.467

8.  Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2.

Authors:  Peng Xu; Hua Zhou; Ya-Zhuo Li; Zhong-Wen Yuan; Chang-Xiao Liu; Liang Liu; Ying Xie
Journal:  Front Pharmacol       Date:  2018-10-26       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.